Accepted for Publication: March 29, 2012.
Published Online: July 16, 2012. doi:10.1001/archneurol.2012.1070
Author Contributions: Data used in the preparation of this article were obtained from the ADNI database (adni.loni.ucla.edu). As such, the investigators within the ADNI study contributed to the design and implementation of ADNI or provided data but did not participate in the analysis or writing of the manuscript. Study concept and design: Soares, Potter, Pickering, Shera, Ferm, Dean, Simon, Siuciak, Koroshetz, Wan, Trojanowski, and Shaw. Acquisition of data: Soares, Potter, Trojanowski, and Shaw. Analysis and interpretation of data: Soares, Potter, Pickering, Kuhn, Immermann, Ferm, Dean, Swenson, Kaplow, Thambisetty, Zagouras, Koroshetz, Wan, Trojanowski, and Shaw. Drafting of the manuscript: Soares, Potter, Pickering, Kuhn, Ferm, Dean, Swenson, Siuciak, Thambisetty, Koroshetz, and Trojanowski. Critical revision of the manuscript for important intellectual content: Soares, Potter, Pickering, Kuhn, Immermann, Shera, Ferm, Simon, Swenson, Siuciak, Kaplow, Zagouras, Koroshetz, Wan, Trojanowski, and Shaw. Statistical analysis: Soares, Pickering, Kuhn, Immermann, Thambisetty, and Trojanowski. Obtained funding: Soares, Potter, Dean, Simon, Siuciak, and Wan. Administrative, technical, and material support: Potter, Simon, Swenson, Siuciak, and Trojanowski. Study supervision: Soares, Wan, and Trojanowski.
Financial Disclosure: Dr Soares reported owning shares in Bristol-Myers Squibb. Mr Immermann and Dr Wan reported owning shares in Pfizer Inc. Dr Simon reported serving as an independent biomarker consultant. Data collection and sharing for this study represent the work of the Biomarkers Consortium Project “Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimer's Disease.” This project was submitted to the Biomarkers Consortium Neuroscience Steering Committee by a subgroup of the ADNI Private Partner Scientific Board for execution and was managed by a Biomarkers Consortium Project Team that includes members from academia, government, and the pharmaceutical industry. Funding for this project was provided through an overage of funds raised by the Foundation for the National Institutes of Health for the ADNI partnership. The entire data set described in the present study, along with the Biomarkers Consortium plasma proteomics project team data primer and statistical analysis plan, are available on the ADNI website (http://adni.loni.ucla.edu).
Funding/Support: The ADNI study is funded by grant U01 AG024904 from the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health and through generous contributions from the following: Abbott, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Amorfix Life Sciences Ltd, AstraZeneca, Bayer HealthCare, BioClinica Inc, Biogen Idec Inc, Bristol-Myers Squibb, Eisai Inc, Elan Pharmaceuticals Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc, GE Healthcare, Innogenetics, NV, Janssen Alzheimer Immunotherapy Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace Inc, Merck & Co Inc, Meso Scale Diagnostics LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc, Servier, Synarc Inc, and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. The ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by grants P30 AG010129 and K01 AG030514 from the National Institutes of Health and by The Dana Foundation.